Virtual Kidney Check and Follow-up
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: population-based screening for chronic kidney disease.
- Who it may be relevant to
- Registry conditions: Kidney Disease, Chronic. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this clinical trial is to determine the most effective way to complete population-based screening for chronic kidney disease (CKD) in First Nations adults in Manitoba. The main questions it aims to answer are: * To identify chronic kidney disease in First Nations adults in Manitoba * To risk stratify patients as low, moderate and high risk of kidney failure and organize active surveillance by risk category * To initiate treatments to prevent to progression of chronic kidney disease in individuals at risk of kidney failure Participants will be randomized to: 1. Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine Albumin Creatinine Ratio 2. Patient and primary care network contact via mail with a letter but no laboratory requisition The primary outcome is the difference between groups in the proportion of individuals who undergo screening for chronic kidney disease within 6 months.
Interventions
- Other population-based screening for chronic kidney disease
Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Primary outcome measures
- The proportion of individuals who undergo screening for Chronic Kidney Disease (CKD) [Time frame: 6 months]
Secondary outcome measures (12)
- New diagnosis of CKD (Chronic Kidney Disease) [Time frame: 5 years]
- Anti-hyperintensive therapy [Time frame: 5 years]
- Renin angiotensin aldosterone inhibitor blockade treatment [Time frame: 5 years]
- Sodium Glucose Cotransporter 2 (SGLT2) inhibition treatment [Time frame: 5 years]
- Mineral corticoid receptor antagonist treatment [Time frame: 5 years]
- Statins treatment [Time frame: 5 years]
- Anti-platelet agents treatment [Time frame: 5 years]
- Hospitalizations for diseases [Time frame: 5 years]
- The number of antihypertensive medications [Time frame: 5 years]
- Change in estimated Glomerular Filtration Rate, urine albumin to creatinine ratio, kidney failure risk equation measurements [Time frame: 5 years]
- estimated Glomerular Filtration Rate slope [Time frame: 5 years]
- Number of individuals with 40 % decline in estimated Glomerular Filtration Rate [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Age>= 18 years
- Resident of Manitoba
- First Nations
- Urban, rural or remote location
Exclusion criteria
- Kidney failure (dialysis or transplant)
- chronic kidney disease (estimated Glomerular Filtration Rate <60 milliliter/1.73square meter for 3 months)
- Screening for chronic kidney disease with estimated Glomerular Filtration Rate or Albumin to Creatinine ratio in the last 2 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Screening
Study locations
Canada · 1 center
- Chronic Disease Innovation Centre — Winnipeg
Identifiers
NCT: NCT06223750 · HS24845 (H2021:170)